October 13, 2026 Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate
October 13, 2026 SEC Qualifies GOA Therapeutics’ Public Offering to Sell Up to $300 Million in Stock; Set for Launch October 15
New “Mammo with Heart” screening provides breast and heart health insights during a routine mammogram
New “Mammo with Heart” screening provides breast and heart health insights during a routine mammogram 
